IHCC
Comprehensive myopia management solution designed to help control progression and improve outcomes
Clinically proven EyeRising's myopia management therapy device device emits a wavelength of 650±10nm at a laser power of 0.29mW going through a 4-mm pupil (very safe to retina) even 1.03mW upto through 7mm are safer) and is used for 3 minutes two times a day with a minimum gap of 4-5 hours for 5 days a week.
Here is a simple tutorial of device to guide you to learn treatment protocols
The device delivers precise 650±10nm wavelength red light at a safe intensity of 0.29 mW through a 4mm pupil. Follow these simple steps for each treatment session:
Maintain regular treatment schedule, missing sessions may reduce effectiveness. Set daily reminders to ensure compliance.
You may continue wearing spectacles during daily activities. Remove them only during the 3-minute treatment sessions.
Keep the device clean and store in the provided case. Avoid exposing to extreme temperatures or moisture.
Keep a treatment log and attend all scheduled follow-up appointments for progress monitoring.
The myopia management has been clinically proven to be safe with:
If you experience any discomfort, discontinue use and contact your eye care professional immediately.
Backed by rigorous scientific research and clinical trials
71.4% effectiveness: Clinical study by Ren et al. (2025) showed significant reduction in axial length by 0.07±0.11mm after 3 months
Improved circulation: Central choroid thickness increased from 255±41 µm to 274±29 µm, alleviating scleral hypoxia
Safe for children: Zero adverse effects on visual acuity, retinal health, or other eye parameters across multiple studies
Non-invasive: 650±10nm wavelength enhances mitochondrial function safely
"Short-term effectiveness and safety of photobiomodulation on low-to-moderate myopia"
Long-term efficacy study demonstrating sustained myopia control benefits
"Orthokeratology and low-intensity laser therapy for slowing myopia progression"